Propanc Biopharma

Propanc Advances PPC-001 Assay Development for Phase 1b Cancer Study

Melbourne, Australia — October 30, 2026 Propanc Biopharma, Inc. announced progress in analytical development activities supporting its planned Phase...

By cGxPwire Editor
October 31, 2026

Bio-Pharma

Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results

Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...

By cGxPwire Editor
August 29, 2026

Bio-Pharma

Propanc Biopharma Advances PRP as a Novel Approach for RAS-Driven Cancers

MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...

By cGxPwire Editor
August 14, 2026

.Clinical

Propanc Biopharma Reports Strong Preclinical PRP Results

MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...